Targeting protein degradation strategies in drug discovery: integrating PROTACs, ubiquitination biology, and AI-driven design

Targeted protein degradation (TPD) has emerged as a transformative therapeutic strategy for eliminating disease-associated proteins, including targets that remain challenging to modulate using conventional occupancy-driven inhibitors. Among TPD approaches, proteolysis-targeting chimeras (PROTACs) exploit the ubiquitin–proteasome system (UPS) to induce selective and event-driven degradation of proteins of interest (POIs). Despite rapid advances in PROTAC development, successful translation depends on interconnected determinants, including target degradability, ubiquitin ligase (E3) recruitment, warhead and linker properties, ternary-complex formation, ubiquitination efficiency, intracellular exposure, and pharmacokinetic behavior. This review provides an integrated, mechanism-oriented analysis of these determinants by linking PROTAC design, ubiquitination biology, computational approaches, and clinical development. We examine key principles governing PROTAC-mediated degradation, with emphasis on E3-ligase selection, linker design, ternary-complex geometry and cooperativity, ubiquitin (Ub)-acceptor lysine (Lys) accessibility, ubiquitin-conjugating enzyme (E2)/E3 context, proteasomal engagement, inefficient degradation, and the hook effect. Recent advances in artificial intelligence (AI) and machine learning for degradation-activity prediction, E3-ligase/POI pairing, ligand and linker optimization, ternary-complex modeling, and absorption, distribution, metabolism, excretion, and toxicity (ADMET) assessment are critically evaluated alongside their technical and translational limitations. Preclinical developments, clinical-stage degraders, emerging TPD modalities, and major barriers to translation are also discussed. We propose an integrated framework linking distinct target ubiquitination patterns, degrader design, ternary-complex geometry, AI-enabled prediction, and pharmacokinetic/clinical constraints, providing a mechanism-informed roadmap for the rational development of next-generation protein degraders and identifying mechanistic bottlenecks and translational priorities across therapeutic settings.

Authors

Institutions

Publication Details

Journal
Molecular Biomedicine
Published
2026-11-21
DOI
https://doi.org/10.1186/s43556-026-00649-4
Primary Topic
Protein Degradation and Inhibitors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting protein degradation strategies in drug discovery: integrating PROTACs, ubiquitination biology, and AI-driven design

Chandra Sekhar Bhol, Gautam Sethi, Li Wang, Sanjeevi Pandiyan
Molecular Biomedicine
Protein Degradation and Inhibitors
article

Targeting protein degradation strategies in drug discovery: integrating PROTACs, ubiquitination biology, and AI-driven design

Chandra Sekhar Bhol, Gautam Sethi, Li Wang, Sanjeevi Pandiyan
article en

Abstract

Targeted protein degradation (TPD) has emerged as a transformative therapeutic strategy for eliminating disease-associated proteins, including targets that remain challenging to modulate using conventional occupancy-driven inhibitors. Among TPD approaches, proteolysis-targeting chimeras (PROTACs) exploit the ubiquitin–proteasome system (UPS) to induce selective and event-driven degradation of proteins of interest (POIs). Despite rapid advances in PROTAC development, successful translation depends on interconnected determinants, including target degradability, ubiquitin ligase (E3) recruitment, warhead and linker properties, ternary-complex formation, ubiquitination efficiency, intracellular exposure, and pharmacokinetic behavior. This review provides an integrated, mechanism-oriented analysis of these determinants by linking PROTAC design, ubiquitination biology, computational approaches, and clinical development. We examine key principles governing PROTAC-mediated degradation, with emphasis on E3-ligase selection, linker design, ternary-complex geometry and cooperativity, ubiquitin (Ub)-acceptor lysine (Lys) accessibility, ubiquitin-conjugating enzyme (E2)/E3 context, proteasomal engagement, inefficient degradation, and the hook effect. Recent advances in artificial intelligence (AI) and machine learning for degradation-activity prediction, E3-ligase/POI pairing, ligand and linker optimization, ternary-complex modeling, and absorption, distribution, metabolism, excretion, and toxicity (ADMET) assessment are critically evaluated alongside their technical and translational limitations. Preclinical developments, clinical-stage degraders, emerging TPD modalities, and major barriers to translation are also discussed. We propose an integrated framework linking distinct target ubiquitination patterns, degrader design, ternary-complex geometry, AI-enabled prediction, and pharmacokinetic/clinical constraints, providing a mechanism-informed roadmap for the rational development of next-generation protein degraders and identifying mechanistic bottlenecks and translational priorities across therapeutic settings.

Molecular BiomedicineVol. 7(1)
National University of Singapore (SG), Nantong University (CN)
Protein Degradation and Inhibitors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon